• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与跨国临床试验同时进行的经济评估。GUSTO IIb研究考量

Economic evaluation alongside multinational clinical trials. Study considerations for GUSTO IIb.

作者信息

Jönsson B, Weinstein M C

机构信息

Stockholm School of Economics.

出版信息

Int J Technol Assess Health Care. 1997 Winter;13(1):49-58. doi: 10.1017/s0266462300010229.

DOI:10.1017/s0266462300010229
PMID:9119623
Abstract

Data relevant to economic evaluation are being collected alongside clinical trials with increasing frequency. When these trials involve health outcomes and resource utilization in many different countries, numerous methodologic problems arise. This paper describes and discusses the methodology for economic evaluation that will be used in the Economic Substudy of GUSTO IIb, as an example of how to address the problems that arise in economic evaluations linked to international trials.

摘要

与经济评估相关的数据正越来越频繁地在临床试验过程中收集。当这些试验涉及许多不同国家的健康结果和资源利用情况时,就会出现众多方法学问题。本文描述并讨论了将在GUSTO IIb经济子研究中使用的经济评估方法,以此作为如何解决与国际试验相关的经济评估中出现的问题的一个示例。

相似文献

1
Economic evaluation alongside multinational clinical trials. Study considerations for GUSTO IIb.与跨国临床试验同时进行的经济评估。GUSTO IIb研究考量
Int J Technol Assess Health Care. 1997 Winter;13(1):49-58. doi: 10.1017/s0266462300010229.
2
Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
Eur Heart J. 1998 Oct;19(10):1518-24. doi: 10.1053/euhj.1998.1092.
3
Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.与常规糖蛋白IIB/IIIA抑制的肝素相比,临时糖蛋白IIB/IIIA抑制的比伐卢定用于经皮冠状动脉介入治疗的经济学评价:REPLACE-2试验结果
J Am Coll Cardiol. 2004 Nov 2;44(9):1792-800. doi: 10.1016/j.jacc.2004.05.085.
4
A second look at bivalirudin.
Am Heart J. 2001 Dec;142(6):929-31. doi: 10.1067/mhj.2001.119375.
5
Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction.比伐卢定与肝素加糖蛋白 IIb/IIIa 抑制剂治疗急性 ST 段抬高型心肌梗死的成本效益比较。
Heart. 2012 Apr;98(7):544-51. doi: 10.1136/heartjnl-2011-301323. Epub 2012 Feb 7.
6
Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction.新溶栓方案安全性和有效性评估(ASSENT - 3)研究的经济学分析:急性心肌梗死再灌注策略的成本
Am Heart J. 2005 Apr;149(4):637-44. doi: 10.1016/j.ahj.2004.02.019.
7
Economic evaluation of desirudin vs heparin in deep vein thrombosis prevention after hip replacement surgery.髋置换术后预防深静脉血栓形成时地西卢定与肝素的经济学评价
Pharmacoeconomics. 1998 Jan;13(1 Pt 2):111-8. doi: 10.2165/00019053-199813010-00010.
8
Cost-effectiveness analysis of antithrombotic therapy in nonurgent percutaneous coronary intervention.非紧急经皮冠状动脉介入治疗中抗血栓治疗的成本效益分析
Pharmacotherapy. 2006 May;26(5):609-18. doi: 10.1592/phco.26.5.609.
9
Cost analysis of bivalirudin in percutaneous coronary intervention.比伐卢定在经皮冠状动脉介入治疗中的成本分析
J Invasive Cardiol. 2000 Dec;12 Suppl F:37F-40.
10
Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators.急性心肌梗死直接凝血酶抑制与肝素联合纤溶治疗的随机对照比较:GUSTO-IIb试验结果。急性冠状动脉综合征全球开放闭塞冠状动脉策略(GUSTO-IIb)研究人员。
J Am Coll Cardiol. 1998 Jun;31(7):1493-8. doi: 10.1016/s0735-1097(98)00138-7.

引用本文的文献

1
OARSI Clinical Trials Recommendations: Key analytic considerations in design, analysis, and reporting of randomized controlled trials in osteoarthritis.骨关节炎研究学会(OARSI)临床试验建议:骨关节炎随机对照试验设计、分析及报告中的关键分析考量因素
Osteoarthritis Cartilage. 2015 May;23(5):677-85. doi: 10.1016/j.joca.2015.03.011.
2
Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.雷珠单抗和贝伐单抗治疗年龄相关性黄斑变性的成本效益:IVAN随机试验的2年结果
BMJ Open. 2014 Jul 29;4(7):e005094. doi: 10.1136/bmjopen-2014-005094.
3
Clinical trials in orthopaedics research. Part III. Overcoming operational challenges in the design and conduct of randomized clinical trials in orthopaedic surgery.
骨科研究中的临床试验。第三部分。克服骨科手术随机临床试验设计与实施中的操作挑战。
J Bone Joint Surg Am. 2012 Mar 21;94(6):e35. doi: 10.2106/JBJS.K.00009.
4
Bayesian modelling of healthcare resource use in multinational randomized clinical trials.贝叶斯模型在多国家随机临床试验中的医疗资源利用分析。
Pharmacoeconomics. 2009;27(12):1017-29. doi: 10.2165/11314030-000000000-00000.
5
Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma.布地奈德/福莫特罗用于维持和缓解治疗与沙美特罗/氟替卡松加沙丁胺醇治疗哮喘的成本效益比较。
Pharmacoeconomics. 2006;24(7):695-708. doi: 10.2165/00019053-200624070-00008.
6
Design, analysis and presentation of multinational economic studies: the need for guidance.跨国经济研究的设计、分析与呈现:指导的必要性。
Pharmacoeconomics. 2002;20(2):75-90. doi: 10.2165/00019053-200220020-00001.
7
Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease.奥美拉唑和雷尼替丁间歇治疗有症状的胃食管反流病的成本效益
Pharmacoeconomics. 1999 Nov;16(5 Pt 1):483-97. doi: 10.2165/00019053-199916050-00006.
8
Hospital selection for unit cost estimates in multicentre economic evaluations. Does the choice of hospitals make a difference?多中心经济评估中单位成本估计的医院选择。医院的选择会产生影响吗?
Pharmacoeconomics. 1999 Jun;15(6):561-72. doi: 10.2165/00019053-199915060-00004.